{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:05:15Z","timestamp":1792458315016,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,27]],"date-time":"2018-07-27T00:00:00Z","timestamp":1532649600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13075-018-1653-5","type":"journal-article","created":{"date-parts":[[2018,7,27]],"date-time":"2018-07-27T05:29:15Z","timestamp":1532669355000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSARTROS study"],"prefix":"10.1186","volume":"20","author":[{"given":"Eleni","family":"Kampylafka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"d\u2019Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Linz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Lerchen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Stemmler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Englbrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sticherling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Rech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnd","family":"Kleyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Schett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6454-1234","authenticated-orcid":false,"given":"Axel J.","family":"Hueber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,27]]},"reference":[{"issue":"21","key":"1653_CR1","first-page":"2095","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(21):2095\u20136.","journal-title":"N Engl J Med."},{"issue":"1","key":"1653_CR2","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/art.38892","volume":"67","author":"JU Scher","year":"2015","unstructured":"Scher JU, Ubeda C, Artacho A, Attur M, Isaac S, Reddy SM, et al. Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease. Arthritis Rheumatol. 2015;67(1):128\u201339.","journal-title":"Arthritis Rheumatol"},{"issue":"10086","key":"1653_CR3","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1016\/S0140-6736(17)31427-7","volume":"389","author":"P Mease","year":"2017","unstructured":"Mease P. New pathways of treatment for psoriatic arthritis. Lancet (London, England). 2017;389(10086):2268\u201370.","journal-title":"Lancet (London, England)"},{"issue":"6","key":"1653_CR4","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/ar4414","volume":"15","author":"DJ Veale","year":"2013","unstructured":"Veale DJ. Psoriatic arthritis: recent progress in pathophysiology and drug development. Arthritis Res Ther. 2013;15(6):224.","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"1653_CR5","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/nm.3260","volume":"19","author":"G Schett","year":"2013","unstructured":"Schett G, Elewaut D, McInnes IB, Dayer JM, Neurath MF. How cytokine networks fuel inflammation: toward a cytokine-based disease taxonomy. Nat Med. 2013;19(7):822\u20134.","journal-title":"Nat Med"},{"issue":"9999","key":"1653_CR6","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","volume":"386","author":"IB McInnes","year":"2015","unstructured":"McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England). 2015;386(9999):1137\u201346.","journal-title":"Lancet (London, England)"},{"issue":"1","key":"1653_CR7","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"PJ Mease","year":"2017","unstructured":"Mease PJ, van der Heijde D, Ritchlin CT, Okada M, Cuchacovich RS, Shuler CL, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76(1):79\u201387.","journal-title":"Ann Rheum Dis"},{"issue":"14","key":"1653_CR8","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","volume":"373","author":"PJ Mease","year":"2015","unstructured":"Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373(14):1329\u201339.","journal-title":"N Engl J Med"},{"issue":"8","key":"1653_CR9","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1002\/art.39685","volume":"68","author":"D van der Heijde","year":"2016","unstructured":"van der Heijde D, Landewe RB, Mease PJ, McInnes IB, Conaghan PG, Pricop L, et al. Brief report: Secukinumab provides significant and sustained inhibition of joint structural damage in a phase III study of active psoriatic arthritis. Arthritis Rheumatol. 2016;68(8):1914\u201321.","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"1653_CR10","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nrrheum.2017.188","volume":"13","author":"G Schett","year":"2017","unstructured":"Schett G, Lories RJ, D\u2019Agostino MA, Elewaut D, Kirkham B, Soriano ER, et al. Enthesitis: from pathophysiology to treatment. Nat Rev Rheumatol. 2017;13(12):731\u201341.","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"1653_CR11","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S0002-9440(10)62961-6","volume":"167","author":"MI Koenders","year":"2005","unstructured":"Koenders MI, Lubberts E, Oppers-Walgreen B, van den Bersselaar L, Helsen MM, Di Padova FE, et al. Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1. Am J Pathol. 2005;167(1):141\u20139.","journal-title":"Am J Pathol"},{"issue":"1","key":"1653_CR12","doi-asserted-by":"publisher","first-page":"R29","DOI":"10.1186\/ar2936","volume":"12","author":"IE Adamopoulos","year":"2010","unstructured":"Adamopoulos IE, Chao CC, Geissler R, Laface D, Blumenschein W, Iwakura Y, et al. Interleukin-17A upregulates receptor activator of NF-kappaB on osteoclast precursors. Arthritis Res Ther. 2010;12(1):R29.","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"1653_CR13","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1084\/jem.20061775","volume":"203","author":"K Sato","year":"2006","unstructured":"Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med. 2006;203(12):2673\u201382.","journal-title":"J Exp Med"},{"issue":"9","key":"1653_CR14","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1172\/JCI5703","volume":"103","author":"S Kotake","year":"1999","unstructured":"Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest. 1999;103(9):1345\u201352.","journal-title":"J Clin Invest"},{"issue":"7","key":"1653_CR15","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/nm.2817","volume":"18","author":"JP Sherlock","year":"2012","unstructured":"Sherlock JP, Joyce-Shaikh B, Turner SP, Chao CC, Sathe M, Grein J, et al. IL-23 induces spondyloarthropathy by acting on ROR-gammat+ CD3+CD4-CD8- entheseal resident T cells. Nat Med. 2012;18(7):1069\u201376.","journal-title":"Nat Med"},{"issue":"7","key":"1653_CR16","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/nm.2854","volume":"18","author":"RJ Lories","year":"2012","unstructured":"Lories RJ, McInnes IB. Primed for inflammation: enthesis-resident T cells. Nat Med. 2012;18(7):1018\u20139.","journal-title":"Nat Med"},{"issue":"10","key":"1653_CR17","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1002\/art.39732","volume":"68","author":"A Reinhardt","year":"2016","unstructured":"Reinhardt A, Yevsa T, Worbs T, Lienenklaus S, Sandrock I, Oberdorfer L, et al. Interleukin-23-dependent gamma\/delta T cells produce Interleukin-17 and accumulate in the Enthesis, aortic valve, and Ciliary body in mice. Arthritis Rheumatol. 2016;68(10):2476\u201386.","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"1653_CR18","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1002\/art.40150","volume":"69","author":"RJ Cuthbert","year":"2017","unstructured":"Cuthbert RJ, Fragkakis EM, Dunsmuir R, Li Z, Coles M, Marzo-Ortega H, et al. Brief report: group 3 innate lymphoid cells in human Enthesis. Arthritis Rheumatol. 2017;69(9):1816\u201322.","journal-title":"Arthritis Rheumatol"},{"issue":"330","key":"1653_CR19","doi-asserted-by":"publisher","first-page":"330ra337","DOI":"10.1126\/scitranslmed.aad8996","volume":"8","author":"O Uluckan","year":"2016","unstructured":"Uluckan O, Jimenez M, Karbach S, Jeschke A, Grana O, Keller J, et al. Chronic skin inflammation leads to bone loss by IL-17-mediated inhibition of Wnt signaling in osteoblasts. Sci Transl Med. 2016;8(330):330ra337.","journal-title":"Sci Transl Med"},{"issue":"10","key":"1653_CR20","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1002\/jbmr.2521","volume":"30","author":"R Kocijan","year":"2015","unstructured":"Kocijan R, Englbrecht M, Haschka J, Simon D, Kleyer A, Finzel S, et al. Quantitative and qualitative changes of bone in psoriasis and psoriatic arthritis patients. J Bone Miner Res. 2015;30(10):1775\u201383.","journal-title":"J Bone Miner Res"},{"issue":"12","key":"1653_CR21","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1136\/annrheumdis-2015-208821","volume":"75","author":"F Faustini","year":"2016","unstructured":"Faustini F, Simon D, Oliveira I, Kleyer A, Haschka J, Englbrecht M, et al. Subclinical joint inflammation in patients with psoriasis without concomitant psoriatic arthritis: a cross-sectional and longitudinal analysis. Ann Rheum Dis. 2016;75(12):2068\u201374.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"1653_CR22","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.3899\/jrheum.090352","volume":"36","author":"M Ostergaard","year":"2009","unstructured":"Ostergaard M, McQueen F, Wiell C, Bird P, Boyesen P, Ejbjerg B, et al. The OMERACT psoriatic arthritis magnetic resonance imaging scoring system (PsAMRIS): definitions of key pathologies, suggested MRI sequences, and preliminary scoring system for PsA hands. J Rheumatol. 2009;36(8):1816\u201324.","journal-title":"J Rheumatol"},{"issue":"11","key":"1653_CR23","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.3899\/jrheum.141462","volume":"42","author":"GA Bruyn","year":"2015","unstructured":"Bruyn GA, Naredo E, Iagnocco A, Balint PV, Backhaus M, Gandjbakhch F, et al. The OMERACT ultrasound working group 10 years on: update at OMERACT 12. J Rheumatol. 2015;42(11):2172\u20136.","journal-title":"J Rheumatol"},{"issue":"1","key":"1653_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000237","volume":"2","author":"MA D\u2019Agostino","year":"2016","unstructured":"D\u2019Agostino MA, Boers M, Wakefield RJ, Berner Hammer H, Vittecoq O, Filippou G, et al. Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept: results from the APPRAISE study. RMD Open. 2016;2(1):e000237.","journal-title":"RMD Open"},{"issue":"5","key":"1653_CR25","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.semarthrit.2017.09.011","volume":"47","author":"CP Figueiredo","year":"2018","unstructured":"Figueiredo CP, Kleyer A, Simon D, Stemmler F, d\u2019Oliveira I, Weissenfels A, et al. Methods for segmentation of rheumatoid arthritis bone erosions in high-resolution peripheral quantitative computed tomography (HR-pQCT). Semin Arthritis Rheum. 2018;47(5):611\u20138.","journal-title":"Semin Arthritis Rheum."},{"issue":"11","key":"1653_CR26","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1002\/art.38794","volume":"66","author":"S Finzel","year":"2014","unstructured":"Finzel S, Sahinbegovic E, Kocijan R, Engelke K, Englbrecht M, Schett G. Inflammatory bone spur formation in psoriatic arthritis is different from bone spur formation in hand osteoarthritis. Arthritis Rheumatol. 2014;66(11):2968\u201375.","journal-title":"Arthritis Rheumatol."},{"issue":"6","key":"1653_CR27","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/j.bone.2008.01.017","volume":"42","author":"JA Macneil","year":"2008","unstructured":"Macneil JA, Boyd SK. Bone strength at the distal radius can be estimated from high-resolution peripheral quantitative computed tomography and the finite element method. Bone. 2008;42(6):1203\u201313.","journal-title":"Bone"},{"issue":"5 Suppl 93","key":"1653_CR28","first-page":"S48","volume":"33","author":"JS Smolen","year":"2015","unstructured":"Smolen JS, Schoels M, Aletaha D. Disease activity and response assessment in psoriatic arthritis using the disease activity index for PSoriatic arthritis (DAPSA). A brief review. Clin Exp Rheumatol. 2015;33(5 Suppl 93):S48\u201350.","journal-title":"Clin Exp Rheumatol."},{"issue":"1","key":"1653_CR29","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/ard.2008.102053","volume":"69","author":"LC Coates","year":"2010","unstructured":"Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis. 2010;69(1):48\u201353.","journal-title":"Ann Rheum Dis."},{"issue":"2","key":"1653_CR30","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.semarthrit.2016.05.010","volume":"46","author":"A Lackner","year":"2016","unstructured":"Lackner A, Duftner C, Ficjan A, Gretler J, Hermann J, Husic R, et al. The association of clinical parameters and ultrasound verified inflammation with patients\u2019 and physicians\u2019 global assessments in psoriatic arthritis. Semin Arthritis Rheum. 2016;46(2):183\u20139.","journal-title":"Semin Arthritis Rheum."},{"issue":"1","key":"1653_CR31","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1136\/ard.2010.132423","volume":"70","author":"S Finzel","year":"2011","unstructured":"Finzel S, Englbrecht M, Engelke K, Stach C, Schett G. A comparative study of periarticular bone lesions in rheumatoid arthritis and psoriatic arthritis. Ann Rheum Dis. 2011;70(1):122\u20137.","journal-title":"Ann Rheum Dis."},{"issue":"7","key":"1653_CR32","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1136\/annrheumdis-2012-201580","volume":"72","author":"S Finzel","year":"2013","unstructured":"Finzel S, Kraus S, Schmidt S, Hueber A, Rech J, Engelke K, et al. Bone anabolic changes progress in psoriatic arthritis patients despite treatment with methotrexate or tumour necrosis factor inhibitors. Ann Rheum Dis. 2013;72(7):1176\u201381.","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"1653_CR33","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13075-016-0998-x","volume":"18","author":"AT Shaw","year":"2016","unstructured":"Shaw AT, Maeda Y, Gravallese EM. IL-17A deficiency promotes periosteal bone formation in a model of inflammatory arthritis. Arthritis Res Ther. 2016;18(1):104.","journal-title":"Arthritis Res Ther."}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-018-1653-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-018-1653-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-018-1653-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T19:07:35Z","timestamp":1564168055000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-018-1653-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,27]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1653"],"URL":"https:\/\/doi.org\/10.1186\/s13075-018-1653-5","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,27]]},"assertion":[{"value":"9 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the PSARTROS study (ClinicalTrials.gov Identifier: NCT02483234), all patients provided written informed consent, and institutional review board\/ethics committee (Ethik-Kommission der Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg) approved the protocol (EC 63_15Az; IRB 2355\/01).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"153"}}